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Summary This study is a case-control study looking to identify factors associated
with frequent use of hospital services (emergency care and admissions) in COPD
patients. Data from 64 patients with moderate-severe COPD (FEV1/FVCp70,
FEV1p50%) were prospectively collected, 32 cases with high consumption of health
resources (COPD-HC) and 32 controls. COPD-HC was defined as a patient diagnosed of
COPD requiring during one year: (1) two or more hospitalizations; (2) three or more
emergency visits; or (3) one admission and two emergency visits. Patients with COPD
and a similar age, FEV1 and PaO2 who required no hospital care during the study year
(1998) were randomly selected as controls. Demographic, clinical and socioeconomic
data were collected from each subject, and evaluations were made of anxiety,
health-related quality of life [measured with the St. George’s Respiratory
Questionnaire (SGRQ)], nutritional parameters, and different therapeutic aspects.
Forced spirometry, resting arterial blood gases, maximal respiratory muscle
pressures and a 6-min walking test were measured in all cases. After applying a
logistic regression model, the variables that finally proved to be independent
predictors of frequent use of hospital services were: treatment with salmeterol, the
presence of cardiac arrhythmias, and increased SGRQ scores. The administration of
inhaled salmeterol multiplied the risk of having COPD-HC criteria by 27.4 (95%CI:
2.4–308.1), while the presence of arrhythmias multiplied the probability of meeting
high consumption criteria by 24.3 (95%CI: 1.7–340.1). For each point of worsened
quality of life, the risk of hospital care increased 1.06-fold (95%CI: 1.01–1.10).
Although a severity bias related to the presence of long-acting b2-agonists in the
final regression equation cannot be ruled out, the variables associated in our sample
to an increased utilization of hospital services are the regular use of inhaled
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quality of life. The use of specific strategies aimed at modulating these aspects
could, at least in theory, reduce the number of exacerbations requiring hospital
care, with the resultant individual and collective benefits derived.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Chronic obstructive pulmonary disease (COPD) has
become one of the main causes of morbidity and
mortality worldwide. In Spain, the estimated pre-
valence of the disease among the adult population
aged 40–69 years is 9.1%,1 and COPD is the fourth
leading cause of death,2 surpassed only by cancer
and cardiac and cerebrovascular diseases. According
to estimates of the National Health Heart, Lung and
Blood Institute, the annual cost of COPD in the
United States was 23.9 billion US dollars in 1993,
with an average expenditure per patient and year of
1522 US dollars, almost three times the cost per
capita of asthma.3 In Spain, the cost of medical care
associated with COPD during 1998 was estimated to
be a little over 1.21 billion Euros.4 Among the direct
costs, the category with the greatest impact both in
Spain and the United States was hospital expenses,
which according to American studies could exceed
72% of the total direct costs of the disease.5 These
same sources point to the existence of a group of
patients with high consumption of health resources
(COPD-HC); while these patients account for only
10% of all COPD cases, they would account for 73% of
the total expenditure.5 In a previous study we found
that 60.8% of hospital emergencies and 57.1% of all
hospitalizations attributable to exacerbation of
COPD correspond to this target population.6 This
subgroup of patients generally showed a higher
severity profile, with lower forced expiratory vo-
lume in one second (FEV1) values, increased hypox-
emia and older age. However, seriously ill patients
are often seen who hardly ever visit the hospital.
This fact suggests a working hypothesis whereby in
addition to being conditioned by the severity of the
disease itself, the need for hospital care is very
likely to be also modulated by other factors not
currently identified. The purpose of this study was to
attempt and identify these other factors predicting
hospital care in the target population of COPD
patients with high consumption of health resources.
Material and methods
Patient selection
A case-control study was conducted in 64 patients
diagnosed of COPD. The inclusion criteria were a
history of smoking (420 packs/year), and a
FEV1p50% the predicted value, with a FEV1/FVC
ratiop70%. The patients were selected from a
larger Spanish study designed to establish the
hospital care impact of COPD.6 First, we identified
patients (cases and controls) and then we prospec-
tively did the evaluations. The cases consisted of
all patients who met the criteria for COPD-HC in
the year before the start of the study (1998). A
patient was considered to meet COPD-HC criteria
when any of the following conditions had occurred
during that year: (a) two or more hospital admis-
sions for COPD decompensation; (b) three or more
emergency visits for the same reason nor requiring
hospital admission; or (c) one admission and two
emergency visits for COPD exacerbation. Exacer-
bation of COPD was defined as any increase in
respiratory symptoms compared to the baseline
condition of the patient that required a change in
standard medication and made hospital care
necessary. The control group consisted of patients
who required no hospital care during 1998 and were
similar to the corresponding case in terms of age,
resting arterial oxygen pressure (PaO2) and FEV1.
One control was randomly selected for each case.
Data collection
Demographic data were recorded for each patient,
including distance from the hospital (in kilometers)
and socioeconomic status based on a three-level
index adapted from Prescott et al.7: (a) low
socioeconomic index, comprising patients with
limited education (less than 10 years) and a low
income (o450 Euros/month); (b) intermediate
socioeconomic index (i.e., patients belonging
neither to level (a) nor (c); and (c) high socio-
economic index, comprising patients with greater
education (414 years) and a medium to high
income (4900 Euros/month). The clinical variables
recorded consisted of respiratory symptoms, the
existence of comorbidity, and the presence of
complications related to COPD. The respiratory
symptoms recorded were those reported by the
patients at the time of the interview. All patients
were asked about the estimated duration of the
disease (in years). Dyspnea was evaluated by
Mahler’s baseline dyspnea index (BDI).8 Comorbid-
ity was recorded as concomitant cardiac, neurolo-
gical or gastrointestinal diseases, chronic renal
ARTICLE IN PRESS
Risk factors of emergency care 319
failure, neoplastic conditions or other respiratory
diseases. The presence of cardiac arrhythmias was
not regarded as cardiac comorbidity but rather as a
possible complication of COPD. Complications
related to COPD were taken to be the presence of
respiratory failure, chronic cor pulmonale, cardiac
rhythm disorders, or primary bronchogenic carci-
noma. Pulmonary hypertension was not analyzed.
The Spanish version of St. George’s Respiratory
Questionnaire (SGRQ) was used to analyze health-
related quality of life (HRQoL).9 This questionnaire
consists of 50 items (covering 76 levels), in turn
divided into three subscales of symptoms, activity
and impact. The score ranges from 0 to 100, where
0 indicates no HRQoL impairment. Anxiety was
assessed by the State-Trait Anxiety Inventory (STAI-
S/T),10 a self-administered questionnaire that
includes two independent scales which evaluate
different aspects of anxiety: as state (S) and as
trait (T). The former refers to how the individual
feels at that time, while the latter refers to how
the patient feels in general. On each scale, the
patient is required to answer 20 questions which
are scored from 0 (‘‘none’’ on the STAI-S; ‘‘almost
never’’ on the STAI-T) to 3 (‘‘much’’ on the STAI-S;
‘‘almost always’’ on the STAI-T); thus, the final
score can range from a minimum of 0 to a maximum
of 60 points. An individual is considered to suffer
from an anxiety disorder when the STAI-T score
exceeds 38 points. The following anthropometric
parameters were measured to establish the nutri-
tional status of the patients: weight, height,
tricipital skin folds and the mid-arm muscle
circumference of the non-dominant arm. Based on
these measurements, the following indices and
values were calculated: body mass index (BMI),
muscle perimeter of the arm, mid-arm muscle area
(MAMA), and mid-arm fat area (MAFA). Skin folds
were measured with a Holtain lipocalibrator using
the standard method in nutritional studies.11 Folds
were always measured by the same examiner with
the patient under relaxed conditions. The final
measure was the average of three consecutive
measurements of each fold. All patients were
subjected to blood tests under baseline conditions,
with measurement of albumin (mg/dl) and trans-
ferrin (mg/dl) levels.
Forced spirometry (Autospiro AS-600 spirometer,
Minato Medical Science, S.A.) was used to measure
FEV1 and forced vital capacity (FVC) according
to the procedure established by the Sociedad
Espa*nola de Neumolog!ıa y Cirug!ıa Tor!acica (SEPAR).12
The results of FEV1 and FVC are expressed as
percentages of the adult reference values.13
Arterial blood samples were collected and ana-
lyzed according to the method recommended by
the SEPAR.14 Both spirometry and arterial blood
gases were measured in a stable phase, i.e. more
than two months after an exacerbation. The
classical procedure described by Black and Hyatt
was used to measure the maximal respiratory
muscle pressures.15 The theoretical values used
are those reported by Morales et al.16 The 6-min
walking test (6MWT) was performed along a 32-m
corridor of the hospital, according to the protocol
established by Butland et al.17 During the test,
arterial oxygen saturation (SaO2) was continuously
measured using a pulsioxymeter (Pulsox-5, Minolta.
AVL Medical Instruments AG). The test was re-
peated twice, both on the same day and at least
one hour apart. The best result was used for
subsequent data analysis. As reference equations
we used those reported by Enright and Sherrill.18
The treatment received by each patient at the
time of the interview was recorded. None of the
patients had previously undergone lung reduction
surgery or non-invasive mechanical ventilation at
home.
Statistical analysis
The quantitative data are given as the mean7
standard deviation (SD). A w2 test was used to
compare proportions. The Student–Fisher t-test for
non-paired samples was used to compare means,
after checking the assumption of normality by the
Kolmogorov–Smirnov test. The quantitative vari-
ables not following a normal distribution were
compared using the Mann–Whitney’s U-test. The
assumed alpha error was 0.05. For all variables
showing statistically significant differences be-
tween the study groups in the univariate analysis,
a Pearson correlation ðrÞ was applied for quantita-
tive data, and a Spearman ordinal correlation ðrsÞ
for qualitative data, in order to avoid collinearity
between variables. Among variables mutually cor-
related with r or rsX0:6; we selected for subse-
quent multivariate analysis those whose
significance level was greatest in the previous
univariate study. A multivariate analysis applying
logistic regression was performed to all the data
that passed the above screening process. The
statistical software used for data processing was
SPSS version 9 for Windows.
Results
The mean age of the 64 patients was 7278 years;
they all were males. Table 1 shows the baseline
characteristics of both groups for the main con-
founding variables (age, FEV1 and PaO2). The
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control group showed a higher mean PaCO2
[45.177.7 vs. 49.677.8mmHg, P ¼ 0:03].
Univariate analysis
There were no significant differences between
groups in smoking habit, distance between the city
of origin and the hospital, or the modified socio-
economic index (Table 2). Both the general BDI
scale and the subscales of functional impairment,
task magnitude and effort magnitude were signifi-
cantly superior in patients with COPD-HC (Table 2).
Comorbidity was similar in both groups (Table 3).
Fig. 1 summarizes the complications related to
COPD in each group. Significant differences were
only found between the groups in the presence of
cardiovascular arrhythmias, which were more
common in the patients with COPD-HC. Only one
control (3.3%) had chronic atrial fibrillation, as
compared to 12 cases (37.5%). The odds ratio (OR)
was 18.6 (95%CI-OR: 2.2–154.3). No differences
were found for the rest of variables, though
statistical significance was almost reached in
the presence of chronic cor pulmonale, which
was somewhat more frequent among the cases
ðP ¼ 0:08Þ:
HRQoL, as measured by the SGRQ, was signifi-
cantly worse among the cases with COPD-HC, both
in the overall scale and in the symptoms, activity
and impact subscales (Fig. 2). The mean scores
obtained with the STAI-S and STAI-T questionnaires
were within the normal range [15.9 (10.5) and 22.2
(10.6), respectively]. No significant differences
were seen between the two groups for anxiety-
state or anxiety-trait.
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Table 1 Baseline characteristics of cases and controls.
Cases ðn ¼ 32Þ Controls ðn ¼ 32Þ P
Age (years) 7277 7179 NS
PaO2 (mmHg) 61.1711.9 61.979.9 NS
PaCO2 (mmHg) 45.177.7 49.677.8 0.03
FEV1 (ml) 8067250 8377224 NS
FEV1 (%) 33.0712.1 36.879.9 NS
FEV1 pb (ml) 8867272 9027242 NS
FEV1 pb: post bronchodilator FEV1. Data are given as mean7standard deviation (SD).
Table 2 General, demographic and clinical data.
Cases ðn ¼ 32Þ Controls ðn ¼ 32Þ P
Smoking (packets/year) 58.2733.5 56.6743.9 NS
Current smoker status NS
Active 5 (15.6) 8 (25.0%)
Ex-smoker 27 (84.4%) 24 (75.0%)
Distance to hospital (km) 14.8717.5 14.9717.8 NS
Socioeconomic index NS
Low 19 (59.4) 28 (87.5)
Middle 12 (37.5) 2 (6.2)
High 1 (3.1) 2 (6.2)
Dyspnea (BDI)
Functional impairment 1.871.0 2.471.1 0.032
Task magnitude 1.670.7 2.370.8 0.001
Effort magnitude 1.470.8 2.070.8 0.006
Global 4.872.4 6.772.5 0.004
Quantitative data are given as mean7standard deviation (SD). Qualitative variables are given as the number of cases and their
proportion in brackets. BDI: baseline dyspnea index.
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Table 3 Comorbidity.
Cases ðn ¼ 32Þ Controls ðn ¼ 32Þ P
Overall comorbidityn 15 (46.9%) 9 (28.1%) NS
Cardiovascular comorbidity 10 (31.2%) 5 (15,6%) NS
Chronic heart failure 1 (3.1%) F
Ischemic heart disease 4 (12.5%) F
Valve disease 1 (3.1%) 1 (3.1%)
Hypertensionw 5 (15,6%) 4 (12,5%)
Respiratory comorbidity 4 (12.5%) 2 (6.3%) NS
SAHSz 1 (3.1%) 1 (3.1%)
Residual tuberculosis 3 (9.4%) 1 (3.1%)
Neoplastic comorbidity 3 (9.4%) 2 (6.3%) NS
Bronchogenic carcinoma 1 (3.1%) 1 (3.1%)
Colonic carcinoma 1 (3.1%) F
Skin carcinoma F 1 (3.1%)
Carcinoma of the penis 1 (3.1%) F
Neurological comorbidity 5 (15.6%) 3 (9.4%) NS
Stroke 1 (3.1%) 2 (6.3%)
Epilepsy 2 (6.3%) 1 (3.1%)
Parkinson 1 (3.1%) F
Dementia 1 (3.1%) F
Others 13 (40.6%) 11 (34.4%) NS
Diabetes mellitus 2 (6.3%) 4 (12.5%)
Rheumatic disease 4 (12.5%) 3 (9.4%)
Liver disease 1 (3.1%) 1 (3.1%)
Hypothyroidism 1 (3.1%) F
Others 5 (15.6%) 3 (9.4%)
The data are given as the number of cases and their proportion in brackets.
nSome patients had several diseases simultaneously.
wone patient with arterial hypertension also had concomitant isquemic heart disease.
zSAHS: Sleep apnea–hypoapnea syndrome.
Figure 1 Complications related to COPD. PRF: partial (hypoxemic) respiratory failure; GRF: global (hypoxemic and
hypercapnic) respiratory failure; CPC: chronic cor pulmonale; LC: lung cancer; *Po0:05:
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Table 4 shows the anthropometric and bio-
logical parameters used in the nutritional analysis.
None of the functional respiratory parameters
analyzed showed significant differences between
the groups (Table 5). Significant differences were
only seen during the 6MWT in the percentage
time with SaO2 values below 80%, 70% and 60%.
The time with SaO2o90% during the walking test
was similar in both groups.
Table 6 summarizes the treatment being
received by the patients at the time of the
interview. Patients with COPD-HC used salmeterol
more frequently than the controls. Eleven
cases (34.4%) used salmeterol in its different
presentations, as compared to only one control
(3.1%) [P ¼ 0:003; OR: 16.2 (95% CI-OR: 1.9–135.4].
By contrast, only one case (3.1%) belonging to
the COPD-HC group used formoterol, compared
with 5 controls (15.6%) ðP ¼ 0:19Þ: All patients
treated with salmeterol or formoterol used
the same long-acting bronchodilators prior to
1998.
Logistic regression
The variables shown to be independent predictors
of hospital care consumption among patients with
severe COPD were the presence of arrhythmias, a
poorer HRQoL, and treatment with inhaled salme-
terol (Table 7).
Discussion
Our results suggest that in patients with COPD of
similar severity, the factors most contributing to
repeated use of hospital services (both visits to
emergency departments and hospital admissions)
are the regular use of inhaled salmeterol, the
presence of cardiac arrhythmias and the existence
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Figure 2 St. George’s Respiratory Questionnaire (SGRQ) subscores and global score. *Po0:05; **Po0:01:
Table 4 Nutritional parameters.
Cases ðn ¼ 32Þ Controls ðn ¼ 32Þ P
Weight (kg) 69.5710.7 72.1713.5 NS
Height (cm) 16275 16176 NS
BMI (kg/m2) 26.573.5 28.075.0 NS
Tricipital skin fold (mm) 9.173.5 11.775.1 0.023
Brachial circumference (cm) 26.873.2 28.573.8 NS
Muscle perimeter of the arm (cm) 24.072.7 24.772.7 NS
MAMA (cm2) 46.4710.7 49.2711.2 NS
MAFA (cm2) 11.775.5 15.878.3 0.028
Albumin (mg/dl) 3.970.5 4.370.5 0.018
Transferrin 219.9731.3 222.1731.5 NS
Quantitative data are given as mean7standard deviation (SD). Qualitative variables are given as number of cases and their
proportion in brackets. BMI: body mass index. MAMA: area of the muscle of the arm. MAFA: fat area of the arm.
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of an impaired HRQoL. As regards the latter, and
although its three components (impact, activity
and symptoms) are poorer in patients with COPD-
HC, dyspnea, as main symptom, is the factor that
most conditions the need for repeated hospital
care.
Inhaled salmeterol as a predictor of hospital
care
Various series have shown that salmeterol is a drug
useful and safe in the treatment of COPD.19,20 For
this reason, and because our study was not
specifically designed to evaluate the efficacy and
safety of this substance, its presence in the final
regression equation is an unexpected finding. In our
opinion, the possible explanations of this observa-
tion are varied and not necessarily mutually
exclusive. First, a potential bias (perhaps in
severity) should be considered. Second, inadequate
patient response to the drug could be involved.
Third, it should be evaluated whether salmeterol is
able to produce significant side effects that could
explain the observed phenomenon. Finally, the
possibility of interactions should be assessed.
Lanes et al.,21 in a study of more than 61,000
asthmatic patients, of which 2708 were using
salmeterol, noted that the latter showed signifi-
cantly higher hospitalization percentages and stays
in intensive care units (ICU) than the group treated
with theophyllines. However, after adjusting for
severity, salmeterol was not seen to cause an
increased risk of hospitalization, emergency visits
or stays at ICUs. In this same line, Williams et al.,22
in a case-control study conducted in the United
Kingdom, showed that patients using salmeterol
were not at a greater risk of life-threatening
asthma attacks. In our series we have attempted
to eliminate such severity bias by using controls of
similar age, FEV1 and PaO2. This approach makes it
unlikely that severity is the main reason for the
differences in salmeterol use seen between the two
groups. However, it does not allow to rule out a bias
resulting from hospitalization itself, since prior
hospital admissions could, at least theoretically,
have conditioned the subsequent use of this long-
acting bronchodilator (due to a false severity bias).
All patients treated with salmeterol were regularly
using this drug before January 1998, the year in
which all hospital care reported in this study was
provided, nevertheless we have no data about the
time when such treatment was started, whether it
was prescribed as the result of a previous admis-
sion, or whether a temporal relationship existed
between salmeterol administration and the need
for hospital care. The absence of these data and
the study design do not allow us to establish that
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Table 5 Functional respiratory parameters.
Cases ðn ¼ 32Þ Controls ðn ¼ 32Þ P
Spirometry
FEV1 (ml) 8067250 8377224 NS
FEV1 (%) 33.0712.0 36.879.9 NS
FVC (ml) 18867489 18087426 NS
FVC (%) 60.5716.7 60.4713.4 NS
IC (ml) 10667669 12407739 NS
FEV1/FVC (%) 43.4711.3 46.979.0 NS
Peak respiratory pressures
PImax (cmH2O) 58723 53719 NS
PImax (%) 58.0722.4 51.0717.6 NS
PEmax (cmH2O) 89735 99741 NS
PEmax (%) 52.9722.2 60.4721.2 NS
Walking test (6-min)
Distance (meters) 356.17133.8 371.37137.5 NS
Distance (%) 79.6728.5 85.0726.8 NS
SaO2o90% (% of time) 68.5738.2 77.8732.0 NS
SaO2o80% (% of time) 30.4736.0 21.1736.1 0.032
SaO2o70% (% of time) 9.4718.0 6.0719.9 0.022
SaO2o60% (% of time) 1.473.0 0.472.4 0.030
Quantitative data are given as mean7standard deviation (SD). Qualitative variables are given as number of cases and their
proportion in brackets.
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specific therapies may cause specific long-term
consequences. However, this possibility cannot be
ruled out.
Different pharmacoepidemiological studies sug-
gest a strong association between the increasing
use of regularly administered b2-agonists and a loss
of sensitivity and/or a decrease in the number of
b2-adrenergic receptors, with the resulting loss of
bronchodilator effect.23–25 This phenomenon could
lead to an inadequate patient response to treat-
ment and thus possibly explain our findings. Never-
theless, this observation is controversial, as other
series report no sensitivity loss after treatment
with salmeterol26,27 or formoterol.27 This discre-
pancy in results could be due to multiple factors,
including the different methodological designs used
and the possible differences in the populations
studied. The existence of various polymorphisms in
b2-adrenergic receptors that can cause different
signals and/or different regulation on chronic
exposure to b2-agonists has recently been
reported.28 It has been suggested that such
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Table 6 Pharmacological and non-pharmacological treatment.
Cases ðn ¼ 32Þ Controls ðn ¼ 32Þ P
Ipratropium bromide (inh) 32 (100%) 32 (100%) NS
Salbutamol (inh) 32 (100%) 32 (100%) NS
Regular 20 (62.5%) 26 (81.2%)
As required 12 (37.5%) 6 (18.7%)
Long-acting b2 agonists (inh) 12 (37.5%) 6 (18.7%) NS
Salmeterol 11 (34.4%) 1 (3.1%) 0.003
Formoterol 1 (3.1) 5 (15.6%) NS
Inhaled corticoids 11 (34.4%) 10 (31.3%) NS
Budesonide 6 (18.8%) 8 (25.0%) NS
Fluticasone 5 (15.6%) 2 (6.3%) NS
Oral corticoids (maintenance) 5 (15.6%) 4 (12.5%) NS
Theophyllines 13 (40.6%) 16 (50.0%) NS
Diuretics 11 (34.4%) 3 (9.4%) 0.032
Anticoagulants 4 (13.8%) 0 (0%) 0.049
Home oxygen therapy 19 (59.4%) 12 (37.5%) NS
Pulmonary rehabilitation 10 (31.3%) 6 (18.8%) NS
Anti-influenza vaccination 22 (71.0%) 23 (71.9%) NS
Quantitative data are given as mean7standard deviation (SD). Qualitative variables are given as number of cases and their
proportion in brackets.
Table 7 Regression equation.
Coeff. B SE R Sig. Odds ratio (95%CI)
Arrhythmias 3.19 1.34 0.23 0.017 24.3 (1.7–340.1)
SGRQ score 0.06 0.02 0.25 0.012 1.06 (1.0–1.1)
Salmeterol treatment 3.31 1.23 0.27 0.007 27.4 (2.4–308.5)
Constant 3.98 1.33
SE: standard error of coefficient B; R: correlation coefficient, Sig.: significance level. SGRQ: St. George’s respiratory
questionnaire. The presence of any of the variables found in the equation is scored as 1, and the absence as 0. Quantitative
variables (SGRQ) are scored according to their actual value.
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polymorphisms could be associated to asthma of
different severity, and a relation to the degree of
desensitization to the bronchodilating effect of b-
agonists has even been reported.29 This attractive
hypothesis seen in the context of our study could
account for the greater use of hospital care seen
among patients using long-acting b-agonists admi-
nistered on a regular basis. However, b2-receptor
polymorphism does not seem to explain the
differences seen between salmeterol and formo-
terol in our series.
The third aspect to be considered is the
existence of drug-related side effects. Various
clinical studies have shown that salmeterol has a
good safety profile, with minor side effects that in
most cases are similar to those caused by place-
bo.19,20 These studies have usually been conducted
in outpatients who were generally well controlled
and with no associated comorbidity. However, the
biological effects could be different under condi-
tions closer to the real situation, where patients
often have concomitant diseases or where severe
exacerbations occur requiring simultaneous admin-
istration of other drugs. Cazzola et al.,30 in a series
of patients with COPD, pre-existing heart arrhyth-
mias and hypoxemia, suggested that long-acting b2-
adrenergic drugs may have adverse effects upon
the myocardium, though at the standard doses of
50 mg of salbutamol or 12 and 24 mg of formoterol
they seem to have a good safety margin. The results
of the Italian group not only provide relevant
information about the possible undesirable effect
of salmeterol in our series, but also allow us to
establish an association with the presence of heart
arrhythmias, the second variable seen to be
independently associated with the repeated use
of hospital services. The profile of patients in-
cluded in our study, with advanced disease, marked
hypoxemia and frequent comorbidity, could explain
why long-acting b2-agonists would be capable of
causing undesirable cardiac effects even when no
such effects occur in less advanced disease. A
discrepancy with this notion is raised by the use of
formoterol. This drug not only showed no signifi-
cant association to the existence of cardiovascular
arrhythmias, but was also more frequently used in
the patients selected as controls. The clinical
efficacy and duration of action of formoterol and
salmeterol seem to be very similar.31 Nevertheless,
despite these similarities, there are some interest-
ing differences between the two drugs: (1) the
onset of action of salmeterol is slower than that of
formoterol,32 and (2) salmeterol behaves as a
partial agonist, and formoterol as an almost
complete agonist, in the smooth muscle of the
airways.33 According to the basic principles of
agonist/antagonist interaction, a partial agonist
must occupy more receptors than a complete
agonist to induce the same effect, and also behaves
as a functional antagonist in the presence of a
highly effective agonist, since it activates the same
receptor. Molimard et al.,33 in a recent study in
human bronchial tissue, showed that in the
presence of a contracted bronchus, salmeterol
behaves like a functional antagonist of the most
commonly used total agonists, such as isoprenaline,
fenoterol, terbutaline, and particularly salbuta-
mol. Formeterol showed no such antagonistic
effect, though the maximum relaxation induced
by salbutamol was reduced in the presence of
formoterol pretreatment. If these results are
confirmed in vivo, they could explain why in severe
bronchial obstruction the response to rescue
medication is not as satisfactory in patients
pretreated with salmeterol as in patients regularly
receiving formoterol.
Finally, the fourth aspect requiring consideration
is the existence of interactions. Theophyllines
cause severe tachycardia and arrhythmias even at
serum levels considered to be within the therapeu-
tic range.34 This effect appears to be enhanced in
the presence of salbutamol.35 Based on this, we
could perhaps expect an enhancement of the
arrhythmogenic effect in patients who combine
long-acting bronchodilators and theophyllines.
However, to our knowledge no study has reported
this phenomenon to date. We found no differences
in theophylline use between the two groups
studied, and no differences either in the combined
use of both drugs.
Cardiac arrhythmias as a predictor of
hospital care
Rhythm disorders, both supraventricular and ven-
tricular, are common in patients with COPD, and
their occurrence is included among the causes of
exacerbation. This fact could account for the
increased presence of arrhythmias in patients with
frequent exacerbations. However, it does little to
explain the reason for these arrhythmias in this
special patient subgroup. The presence of pre-
existing coronary disease, hypertension, changes in
arterial blood gases or the use of theophyllines and
b2-agonists have been previously reported as
potential arrhythmogenic factors in COPD.36 The
possible arrhythmogenic effect of salmeterol or
theophyllines in our patients has been discussed
before. Of the rest of causes, the coexistence of
coronary disease could account for some of the
rhythm disorders seen, but not all of them. Three
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(25%) of the 12 cases with heart arrhythmias had a
history of ischemic heart disease. By contrast, none
of the controls had documented ischemic heart
disease. Arterial hypertension was similar in both
groups. Hypercapnia does not seem to be a
discriminating cause, since PaCO2 was even higher
among the controls. The degree of resting hypox-
emia was likewise similar in both groups. However,
during the 6-min walking test, patients with COPD-
HC showed deeper desaturations. The clinical
significance of this recurrent hypoxemia is not
clear. Smith et al.37 have recently studied the
effect of exercise-induced hypoxemia upon myo-
cardial repolarization in patients with severe COPD
by measuring the dynamic effects of hypoxemia
upon QTc dispersion. This electrocardiographic
parameter represents regional differences in car-
diac repolarization and is used as a non-invasive
predictor of ventricular arrhythmias and sudden
death. Under rest conditions, QTc dispersion has
been correlated to ventricular extrasystoles in
patients with COPD.38 However, in the series
reported by Smith et al.,37 the authors found no
evidence that exercise-induced hypoxemia in-
creases QTc dispersion. While such exercise-in-
duced hypoxemia does not appear to be related
to arrhythmias, more prolonged hypoxemia occur-
ring during sleep does appear to be related. Flick
and Block,39 in a classical study, showed that these
cardiac events occur very often at night in patients
with COPD, suggesting arterial desaturation to be
responsible. We did not perform nocturnal oximetry
in our patients, and cannot therefore rule out the
possibility that this hypothetical nocturnal hypox-
emia was the cause of the greater number of
arrhythmias seen.
We have classified rhythm disturbances as possi-
ble complications of COPD because they are some-
times a consequence of the disease itself
(hypoxemia) or of its treatment (theophyllines,
b2-adrenergic agents). However, arrhythmias may
also result from comorbidity. If we had considered
arrhythmias as cardiovascular comorbidity, signifi-
cant differences would very likely have been found
between the two groups, since the ‘‘cases’’ usually
showed a greater comorbidity than the controls.
Miratvilles et al.,40 in a study on outpatients with
less severe disease, noted that comorbidity was an
independent risk factor for hospitalization.
Health-related quality of life (HRQoL) as a
predictor of hospital care
Various authors have previously related a worsening
of HRQoL to an increased frequency of exacerba-
tions,41 admissions42 and even hospital readmis-
sions.43 All these studies, including our own,
demonstrate this association, but the design of
these studies does not allow for a conclusion as to
whether an impaired quality of life contributes as
a cause to exacerbations in such patients or is a
consequence of exacerbations. Osman et al.,43 in a
retrospective study, found that an impaired HRQoL
during the first hospital admission was significantly
associated with the possibility of readmission. By
contrast, Seemungal et al.,41 in a study on 70
patients with moderate to severe COPD, found that
exacerbations caused a significant effect on health
condition. Regardless of whether it is a cause or
consequence, the association of HRQoL and COPD
exacerbation is highly consistent, and the quality of
life questionnaire could therefore be used as a good
indicator to stratify patients by risk of exacerba-
tion, hospitalization or readmission.
In the study by Osman et al.,43 although the
three subscales showed differences between the
patients, the impact subscale showed the greatest
differences in the cases requiring readmission. As in
the above study, a significantly higher score was
found in our series for the three subscales in
patients with COPD-HC, showing that the three
components contribute to predict the need for
hospitalization. However, the symptoms subscale
showed the greatest differences between the two
study groups. This subscale showed a strong
correlation to the basal dyspnea index (BDI),
suggesting dyspnea to be a symptom that greatly
contributes to increased use of hospital services by
patients with COPD-HC.
In COPD, the main mechanisms described for
dyspnea are the sensation of muscular effort,
hypoxemia, hypercapnia, dynamic compression of
the airways, and in cases with pulmonary hyperten-
sion or vascular involvement, stimulation of pres-
sure receptors located in the C fibers of the
vascular endothelium.44 In our study, hypoxemia
was similar in both groups, and PaCO2 was even
higher in the control group. No differences were
seen either in the degree of bronchial obstruction,
and the increased dyspnea seen in patients with
COPD-HC could therefore result from an increased
sensation of muscular effort (related to a possible
myopathy or due to hyperinflation itself) or be
caused by a certain vascular involvement. We did
not study pulmonary hypertension, and are there-
fore unable to rule out this possibility. However,
Kessler et al.,45 in a series of 64 patients with
severe COPD, found pulmonary artery pressure was
the best predictor for hospitalization. In this study,
increased PaCO2 values were also shown to be an
independent risk factor for hospitalization. Unlike
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the French study, we noted a PaCO2 increase in the
control group. Our patients were matched for PaO2
and FEV1, and this may have contributed to this
discrepancy in the results. For a similar degree of
bronchial obstruction, the increased hypercapnia
seen in the control group could be related to
obesity. In our series, BMI was comparatively higher
in the control group (2875 vs. 2673 kg/m2), but
not significantly. Overweight appears to be asso-
ciated with a lesser need for hospitalization. In the
study by Kessler et al.,45 84% of patients with
BMI426 kg/m2 were free of hospital admissions at 1
year.
As to the possible contribution of muscle weak-
ness, Decramer et al.,46 found quadriceps strength
to be associated with a greater number of hospital
admissions. Weakness of the ventilatory muscles
was also greater among the patients with more
hospital admissions, although this parameter did
not reach statistical significance. The authors
related muscle weakness to the increased use of
oral corticoids. In our series, no differences were
seen between the two groups in respiratory muscle
strength or in the 6-min walking test, which has
been related to quadriceps strength by some
authors.47 Likewise, we observed no increased use
of maintenance oral corticoids in patients with
COPD-HC. However, some malnutrition markers
were found in these subjects. Malnutrition may be
a cause of myopathy in COPD, and this possibility
cannot therefore be entirely ruled out. Finally,
mention should be made of the possible role of
hyperinflation as a cause of dyspnea in our patients.
Dynamic hyperinflation occurring during exercise
has been shown to be one of the main determinants
of dyspnea and exercise tolerance in COPD.48
However, to our knowledge no study has analyzed
this variable as a predictor for hospitalization.
Inspiratory capacity (IC) provides indirect measures
of hyperinflation both at rest and during exercise.49
We found no differences between the two groups in
resting IC, though this test was not performed
during exercise; thus, the possibility of an in-
creased dynamic hyperinflation in patients with
COPD-HC cannot be ruled out.
In conclusion, among patients with COPD of
similar severity, the main predictors of hospital
care seen in our series were treatment with inhaled
salmeterol, the presence of cardiac arrhythmias,
and an impaired HRQoL. We think that strategies
intended to correct and modulate these aspects
may afford a substantial reduction in hospital care
in a target population of patients with a high
consumption of health resources. This approach
and multidisciplinary care for this patient subgroup
is most likely to reduce not only hospitalization
costs and emergency care requirements, but also
their consequences in terms of morbidity, mortality
and health-related quality of life. The existence of
a severity bias regarding the possible adverse
effect of salmeterol cannot be definitively ruled
out. We therefore consider it necessary to conduct
new studies, with a larger number of patients, to
investigate the possible negative effect of long
acting b-agonists (especially salmeterol) on hospi-
talization rate.
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